The radiopharmaceutical industry is growing quickly. New therapeutic programmes are moving forward, existing companies are expanding, new production facilities are being built and additional manufacturing capacity is being planned across the market.
Much of the conversation around that growth understandably focuses on facilities, equipment, isotopes, investment and production capacity. These are visible constraints. They can be mapped, budgeted and turned into projects.
There is another constraint that is much harder to build.
Experienced people.
Radiopharmaceutical expertise takes time to develop. The people who truly understand how production, QC, QA, validation, engineering, release and logistics interact in daily operation have usually built that understanding over many years. They have seen processes when they work, but also when they do not. They know what happens when a production delay moves into QC, when a release decision affects the transport window, or when a technically small deviation suddenly becomes operationally significant because there is a patient waiting at the end of the chain.
That kind of experience cannot simply be ordered together with the equipment.
And there are not very many people who have it.
Perhaps more importantly, most of them are already working somewhere.
A growing industry is competing for a small pool of experience
As more radiopharmaceutical organisations expand at the same time, they are increasingly drawing from the same relatively small pool of experienced professionals.
A new company may need people with radiopharmaceutical production experience. An established manufacturer expanding to a second or third site needs them too. Suppliers, engineering organisations, hospitals, CDMOs and equipment companies also need people who understand the field well enough to connect technology with actual radiopharmaceutical operations.
The same is true across Quality, QC, validation and engineering.
That creates a different type of capacity problem.
We can build another facility. We can purchase another hot cell. We can add another production line.
We cannot create ten years of radiopharmaceutical experience in six months.
This does not mean that every future employee needs decades of experience. Quite the opposite. If growth depends on finding enough people who already know everything, the industry will eventually constrain itself.
The more important question is how we use the expertise that already exists to create organisations in which more people can become capable.
The risk is not only that vacancies remain open
When people discuss workforce shortages, the problem is often framed as recruitment: can we find enough operators, QC analysts, QA professionals, validation specialists or technical staff?
Recruitment certainly matters, but the operational risk goes further.
A young organisation can look surprisingly capable because a few experienced people are holding many connections together. They know whom to call. They recognise which issue can wait and which one cannot. They understand the history behind a procedure even when that history is not written down. They can bridge gaps between departments because they have worked on both sides of the interface.
That can be extremely effective during start-up.
It can also hide how dependent the organisation has become on individuals.
As production grows, one expert becomes responsible for several processes. As a second shift is introduced, the same person cannot be present everywhere. As a new site opens, knowledge has to be divided. Eventually the informal network that worked so well during the project phase stops scaling.
The problem then is not necessarily that the organisation has too few people.
It may have too little distributed capability.
That distinction matters.
A facility can be ready before the organisation is
We are used to talking about facility readiness, equipment readiness and validation status. These are essential parts of bringing a radiopharmaceutical operation online.
But technical readiness and operational readiness are not the same thing.
A qualified production system does not tell us whether the organisation knows how to respond when a supplier is late. A validated analytical method does not guarantee that QC turnaround fits the production and release schedule. A procedure can define responsibilities perfectly and still leave people uncertain about who should make a decision when reality does not follow the planned sequence.
This becomes especially important in radiopharmaceutical manufacturing because the different functions are so tightly connected.
Production, QC, packaging, review, release and transport cannot really be optimised separately. A delay in one part of the process immediately consumes time somewhere else. A decision made by one function changes the options available to another. That is why supply-chain thinking in radiopharma has to extend far beyond supplier qualification alone.
The operation therefore depends not only on specialists who are very good at their own discipline, but also on people who understand enough of the surrounding process to recognise the consequence of their decisions.
That broader operational understanding is one of the hardest capabilities to recruit.
It is also one of the most important to develop.
We should use scarce expertise to build capability, not dependency
If experienced radiopharmaceutical professionals are scarce, the answer cannot simply be to place one expert in every role.
There will not be enough of them.
Instead, experienced people need to be used where their knowledge creates leverage.
That means involving them early enough to help design the operating model, not bringing them in shortly before go-live to solve all the problems that were created without them.
They can help identify where professional judgement will actually be required, where interfaces are likely to fail, what knowledge needs to sit within a team and what can remain specialist support. They can help create processes that work for people who do not yet have twenty years of experience, without trying to replace judgement with endless procedural detail.
This is also why training needs to go further than demonstrating that someone has read an SOP.
Procedure knowledge matters, but capability develops when people understand why a process works the way it does, what the critical interfaces are and what happens downstream when they make a decision.
That is particularly important when organisations grow quickly.
If every problem has to be escalated to the handful of people who have seen it before, the organisation has not really transferred the expertise. It has simply created a queue around the experts.
The better outcome is that their experience becomes embedded in the way the operation works.
This changes how we should think about operational readiness
Operational readiness is sometimes treated as one of the final project activities: hire the team, complete the procedures, train everyone and prepare for start-up.
By then, many of the most important decisions have already been made.
The process has been designed. Equipment has been selected. Departmental boundaries have been created. Responsibilities have been assigned. Systems have been chosen.
If the people who understand daily radiopharmaceutical operations only arrive at the end, they inherit that design rather than helping shape it.
A stronger approach is to ask operational questions much earlier.
How will production and QC work together when the schedule changes? How much experienced oversight is really required on each shift? Which decisions can operators make themselves and which genuinely require escalation? Where are we relying on knowledge that currently sits in one person's head? How will a new employee develop from following a procedure to understanding the process behind it?
These are not soft organisational questions.
They influence capacity, reliability, compliance and ultimately whether the facility can do what it was built to do.
They also determine how much scarce expertise the organisation will require once routine operation begins. This is closely connected to the broader question of designing operational reliability before go-live and to the user-side choices discussed in The User Side of Radiopharmaceutical Facility Design.
The workforce problem is therefore also a design problem
There will continue to be competition for experienced radiopharmaceutical professionals.
That is unlikely to disappear simply because the industry needs more of them.
But the size of the talent pool is only one side of the problem. The other is how organisations are designed to use that talent.
An operation that depends on a large number of highly experienced people for routine decisions will be difficult to scale.
An operation that isolates expertise inside individual departments will struggle at the interfaces.
And an organisation that assumes knowledge will somehow transfer from experienced employees to new colleagues simply by working alongside them may eventually discover how much of its capability was never captured at all.
The alternative is not to remove professional judgement. Radiopharmaceutical operations need it.
The challenge is to create an environment in which judgement can develop.
That means clear ownership, understandable processes, deliberate knowledge transfer, strong interfaces and enough experienced people in the right places to coach, challenge and guide others.
It also means accepting that capability building needs to be planned alongside technical capacity.
So who will run the future?
The growth of theranostics creates enormous opportunity.
It also creates a very practical question.
When the facilities are finished, the equipment is qualified and the products are ready, who will operate all of this?
Some of those people are already working in radiopharma today.
Many are not.
The future of the industry therefore cannot depend only on recruiting the relatively small group of people who already have deep radiopharmaceutical experience. We will need those people, but we will also need them to help create the next generation of operational capability.
That requires organisations that do more than employ expertise.
They need to multiply it.
Because the future capacity of radiopharma will not ultimately be determined only by how much we can build.
It will also be determined by how many people we can prepare to run it.
